Labcorp Holdings Inc.
NYSE:LHMedical - Diagnostics & Research
-$3.46 today
- Market cap
- $30.11B
- Beta
- 0.88
- P/E (TTM)
- 22.4
- EPS (TTM)
- $11.44
- Dividend yield
- 1.12%
Volume 0.69M
Average 0.63M
LH EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Labcorp Holdings Inc.NYSE: LH
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows in line with its trailing trend
Q2 FY2026 EBITDA of $620.9M rose 16.7% year over year, ahead of the +15.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 13.3% from the prior quarter. Over 3 fiscal years it compounded at +1.0% a year.
Context
- EBITDA amounted to 14.4% of revenue in FY2025, up 0.5 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of $2.74B (+36.0%) for the fiscal year ending Dec 2026, a step up from the +11.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $620.9M+13.3% QoQ
- Last fiscal yearDec 2025
- $2.01B+11.1% YoY
- LTMJun 2026
- $2.15B+15.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +16.7% | +24.3% | +7.6 pp |
| 1 year | +11.1% | +36.0% | +24.9 pp |
| 3-year CAGR | +1.0% | +15.1% | +14.1 pp |
| 5-year CAGR | +11.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 2.01B USD
- Year-over-year change
- +11.1%
- 4-year CAGR
- -14.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.01B | +11.1% |
| FY2024 | 2024-12-31 | 1.81B | +34.2% |
| FY2023 | 2023-12-31 | 1.35B | -31.0% |
| FY2022 | 2022-12-31 | 1.95B | -46.8% |
| FY2021 | 2021-12-31 | 3.68B | — |
EBITDA vs competitors
How LH compares with its peers on the latest reported figures
- LH's LTM Jun 2026 EBITDA of $2.15B is the 3rd highest of the 7 companies compared; the peer median is $262.34M.
- Its year-over-year change of +15.0% is the 2nd highest of 7, against a peer median of +3.5%.
- EBITDA amounts to 15.0% of revenue for LH, versus a peer median of 28.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $11.24B | -0.8% | -1.3% | 23.7% | |
| LTM Sep 2026 | $2.3B | +7.7% | +6.4% | 19.4% | |
| LTM Jun 2026 | $2.15B | +15.0% | +1.0% | 15.0% | |
| LTM Jun 2026 | $703.39M | -1.6% | -2.7% | 33.5% | |
| LTM Jun 2026 | -$178.71M | +15.6% | — | 6.6% | |
| LTM Jun 2026 | -$374.1M | +10.8% | — | 226.4% | |
| LTM Sep 2026 | -$441.45M | -24.7% | — | 34.5% | |
| Peer median (excluding LH) | $262.34M | +3.5% | -1.3% | 28.6% | |
Competitors are the stored peer set for LH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.14B | 11.86B | 12.16B | 13.01B | 13.95B |
| Cost of Revenue | 8.14B | 8.16B | 8.8B | 9.38B | 10.22B |
| Gross Profit | 4.99B | 3.71B | 3.36B | 3.62B | 3.73B |
| Gross Margin | 38.0% | 31.3% | 27.7% | 27.9% | 26.8% |
| Research & Development | 0 | 0 | 2M | 0 | 0 |
| Selling, General & Admin | 1.69B | 2B | 2.02B | 2.23B | 2.22B |
| Operating Expenses | 1.94B | 2.27B | 2.64B | 2.54B | 2.22B |
| Depreciation & Amortization | 577M | 537.2M | 577.3M | 643.5M | 681.1M |
| EBITDA | 3.68B | 1.95B | 1.35B | 1.81B | 2.01B |
| EBITDA Margin | 28.0% | 16.5% | 11.1% | 13.9% | 14.4% |
| Operating Income | 3.05B | 1.44B | 725.6M | 1.09B | 1.52B |
| Operating Margin | 23.2% | 12.1% | 6.0% | 8.4% | 10.9% |
| Interest Income | 0 | 0 | 0 | 0 | 15.2M |
| Interest Expense | 211.8M | 179.8M | 199.6M | 208.3M | 224.1M |
| Other Income / Expenses | (161M) | (199.1M) | (156.7M) | (127.2M) | (408.7M) |
| Income Before Tax | 2.89B | 1.24B | 568.9M | 959.5M | 1.11B |
| Pre-Tax Margin | 22.0% | 10.4% | 4.7% | 7.4% | 7.9% |
| Income Tax Expense | 690M | 233.9M | 188.5M | 212.4M | 229.8M |
| Net Income | 2.38B | 1.28B | 418M | 746M | 876.5M |
| Net Margin | 18.1% | 10.8% | 3.4% | 5.7% | 6.3% |
| EPS (Basic) | 24.58 | 14.04 | 4.80 | 8.89 | 10.54 |
| EPS (Diluted) | 24.38 | 13.96 | 4.77 | 8.84 | 10.46 |
| Weighted Avg Shares | 96.7M | 91.1M | 87.1M | 83.9M | 83.2M |
| Weighted Avg Shares (Diluted) | 97.5M | 91.6M | 87.6M | 84.4M | 83.8M |
Labcorp Holdings Inc.
NYSE:LH
Intrinsic Alpha fair value
Locked
Current Price
$370.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.